Novasite Pharmaceuticals, Inc Company Profile
Novasite is a drug discovery company using structure-function relationships in validated G protein coupled receptor targets to find better GPCR modulating drugs.Novasite began as a majority-owned subsidiary of Applied Molecular Evolution, Inc. (“AME”), which was acquired by Eli Lilly in 2004 for $400M. Novasite is the exclusive licensee of AME molecular evolution technology, which the Company adapted for the discovery and optimization of small molecule GPCR modulating drugs. Funded by $20 million in private equity and grant revenue, Novasite developed its proprietary technologies, established commercial collaborations and advanced its own internal development programs.
11025 Roselle Street
United States of America
Drugs and Medications
Novasite is a drug discovery company using structure-function relationships in validated G protein coupled receptor targets to find better GPCR modulating drugs.Novasite began as a majority-owned subs...
More Information about "Novasite Pharmaceuticals, Inc" on BioPortfolio
We have published hundreds of Novasite Pharmaceuticals, Inc news stories on BioPortfolio along with dozens of Novasite Pharmaceuticals, Inc Clinical Trials and PubMed Articles about Novasite Pharmaceuticals, Inc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Novasite Pharmaceuticals, Inc Companies in our database. You can also find out about relevant Novasite Pharmaceuticals, Inc Drugs and Medications on this site too.